MX2016012258A - Dosificacion optima de un conjugado del farmaco del anticuerpo-cd19. - Google Patents

Dosificacion optima de un conjugado del farmaco del anticuerpo-cd19.

Info

Publication number
MX2016012258A
MX2016012258A MX2016012258A MX2016012258A MX2016012258A MX 2016012258 A MX2016012258 A MX 2016012258A MX 2016012258 A MX2016012258 A MX 2016012258A MX 2016012258 A MX2016012258 A MX 2016012258A MX 2016012258 A MX2016012258 A MX 2016012258A
Authority
MX
Mexico
Prior art keywords
antibody drug
drug conjugate
optimal dosing
dosing
optimal
Prior art date
Application number
MX2016012258A
Other languages
English (en)
Inventor
Zhao Baiteng
ALBERTSON Tina
han Tae
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2016012258A publication Critical patent/MX2016012258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

La presente invención describe métodos de dosificación óptima de los conjugados del fármaco del anticuerpo-CD19.
MX2016012258A 2014-04-08 2015-04-07 Dosificacion optima de un conjugado del farmaco del anticuerpo-cd19. MX2016012258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461976790P 2014-04-08 2014-04-08
PCT/US2015/024732 WO2015157297A1 (en) 2014-04-08 2015-04-07 Optimal dosing of a cd19-antibody drug conjugate

Publications (1)

Publication Number Publication Date
MX2016012258A true MX2016012258A (es) 2017-01-06

Family

ID=54288332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012258A MX2016012258A (es) 2014-04-08 2015-04-07 Dosificacion optima de un conjugado del farmaco del anticuerpo-cd19.

Country Status (12)

Country Link
US (1) US20170182178A1 (es)
EP (1) EP3129052B1 (es)
JP (1) JP2017512801A (es)
KR (1) KR20160141727A (es)
CN (1) CN106170300A (es)
AU (1) AU2015244004A1 (es)
CA (1) CA2941154A1 (es)
EA (1) EA201692016A1 (es)
IL (1) IL247526A0 (es)
MX (1) MX2016012258A (es)
SG (1) SG11201607133QA (es)
WO (1) WO2015157297A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45625A (fr) * 2016-07-08 2019-05-15 Genmab As Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl
WO2018229222A1 (en) * 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
CN109069584A (zh) * 2017-06-29 2018-12-21 成都华创生物技术有限公司 一种trail类蛋白持续抑制肿瘤细胞生长的给药方法
US11672827B2 (en) 2017-12-23 2023-06-13 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2489364E (pt) * 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
JP5727786B2 (ja) * 2007-10-19 2015-06-03 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１９結合性物質およびその使用
ME02919B (me) * 2010-06-15 2018-04-20 Genmab As Konjugati humanog antitijela sa lijekom protiv tkivnog faktora
AU2011316917B2 (en) * 2010-10-22 2016-02-25 Seagen Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
WO2012162561A2 (en) * 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses

Also Published As

Publication number Publication date
EA201692016A1 (ru) 2017-01-30
EP3129052A4 (en) 2017-11-15
KR20160141727A (ko) 2016-12-09
JP2017512801A (ja) 2017-05-25
SG11201607133QA (en) 2016-09-29
AU2015244004A1 (en) 2016-09-15
CN106170300A (zh) 2016-11-30
EP3129052A1 (en) 2017-02-15
IL247526A0 (en) 2016-11-30
EP3129052B1 (en) 2020-06-03
US20170182178A1 (en) 2017-06-29
WO2015157297A1 (en) 2015-10-15
CA2941154A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
IL252015A0 (en) Antibody drug conjugates
HK1232123A1 (zh) 親水性抗體-藥物偶聯物
IL250189A0 (en) Anti–cdh6 antibody drug conjugates
IL283777A (en) Methods for creating formulations of drug-antibody conjugate preparations
SG11201608309PA (en) Anti-her3 antibody-drug conjugate
EP3154574A4 (en) Homogenous antibody drug conjugates via enzymatic methods
EP3250238A4 (en) Antibody drug conjugates
PL3148591T3 (pl) Koniugaty nanocząstka-lek
EP3253212A4 (en) Antibody drug conjugates
EP3220961C0 (en) THERAPEUTIC VITAMIN D CONJUGATES
GB201614443D0 (en) Targeted drug conjugates
IL253549B (en) Antibody-urease conjugates for therapeutic purposes
IL263965A (en) Cleavable drug polymer conjugates
EP3104882A4 (en) Extracellular targeted drug conjugates
LU92659B1 (en) Glycooptimized antibody drug conjugates
MX2016012258A (es) Dosificacion optima de un conjugado del farmaco del anticuerpo-cd19.
EP3328393A4 (en) CD20-OBJECTIVE EXTRACELLULAR MEDICAMENT CONJUGATES
GB201419996D0 (en) Targeted drug conjugates
GB201418984D0 (en) Novel drug conjugates
GB201407533D0 (en) Targeted drug conjugates
GB201401818D0 (en) Targeted drug conjugates
GB201419994D0 (en) Small molecule drug conjugates
GB201407530D0 (en) Small molecule drug conjugates
GB201401819D0 (en) Small molecule drug conjugates
GB201408176D0 (en) Ligand drug conjugates